Mural Oncology CEO to present at TD Cowen conference; focus on immuno-oncology therapies and trial updates.
Quiver AI Summary
Mural Oncology plc, a clinical-stage immuno-oncology company focused on developing engineered therapies targeting cytokine pathways, announced that CEO Caroline Loew, Ph.D., will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 p.m. ET, with a live webcast available online. The company is developing its lead candidate, nemvaleukin alfa, which is in potential registrational trials for platinum-resistant ovarian cancer and mucosal melanoma, with results expected in early to mid-2025. Mural Oncology is based in Dublin, Ireland, and has primary facilities in Waltham, Massachusetts. More information can be found on their website and social media platforms.
Potential Positives
- CEO Caroline Loew, Ph.D., will present at a prominent health care conference, highlighting the company’s visibility and engagement with investors and industry professionals.
- The upcoming presentation at the TD Cowen conference suggests Mural Oncology is actively marketing its innovative therapies, potentially increasing interest and investment in the company.
- Information about the lead candidate, nemvaleukin alfa, being in potentially registrational trials indicates progress in drug development and potential for future commercialization.
- The anticipated reading of clinical trial results in late Q1/early Q2 and Q2 of 2025 signifies a critical milestone that could positively impact the company's valuation and investor confidence.
Potential Negatives
- None
FAQ
When will Mural Oncology's CEO present at the TD Cowen Conference?
Mural Oncology's CEO, Caroline Loew, Ph.D., will present on March 4, 2025, at 3:10 p.m. ET.
Where can I watch the live webcast of the presentation?
The live webcast of the presentation will be available at https://ir.muraloncology.com/events-and-presentations.
What is Mural Oncology's lead candidate?
Mural Oncology's lead candidate is nemvaleukin alfa, targeting treatments for platinum-resistant ovarian cancer and mucosal melanoma.
What types of cancer is Mural Oncology focusing on?
Mural Oncology is focusing on immunotherapies for platinum-resistant ovarian cancer and mucosal melanoma.
How can I get more information about Mural Oncology?
More information about Mural Oncology can be found on their website at www.muraloncology.com and their LinkedIn and X pages.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MURA Insider Trading Activity
$MURA insiders have traded $MURA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $MURA stock by insiders over the last 6 months:
- ADAM D. CUTLER (Chief Financial Officer) sold 7,421 shares for an estimated $25,305
- VICKI L GOODMAN (Chief Medical Officer) sold 5,069 shares for an estimated $16,879
- CAROLINE LOEW (Chief Executive Officer) sold 2,763 shares for an estimated $9,394
- MAIKEN KESON-BROOKES (See Remarks) sold 2,555 shares for an estimated $8,354
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MURA Hedge Fund Activity
We have seen 25 institutional investors add shares of $MURA stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 743,495 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $2,327,139
- ALTA FUNDAMENTAL ADVISERS LLC removed 720,143 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,318,860
- ACADIAN ASSET MANAGEMENT LLC removed 296,432 shares (-77.7%) from their portfolio in Q4 2024, for an estimated $954,511
- CENTIVA CAPITAL, LP removed 203,706 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $655,933
- VERITION FUND MANAGEMENT LLC removed 132,928 shares (-39.1%) from their portfolio in Q4 2024, for an estimated $428,028
- ALPINE GLOBAL MANAGEMENT, LLC removed 129,624 shares (-61.6%) from their portfolio in Q4 2024, for an estimated $417,389
- POINT72 ASSET MANAGEMENT, L.P. removed 108,715 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $350,062
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cowen 45 th Annual Health Care Conference on March 4, 2025 and 3:10 p.m. ET. A live webcast of the presentation will be available at https://ir.muraloncology.com/events-and-presentations . A replay of the webcast will be archived and available following the event.
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. Our lead candidate, nemvaleukin alfa, is currently in potentially registrational trials in platinum-resistant ovarian cancer and mucosal melanoma reading out in late Q1/early Q2 and Q2 of 2025, respectively. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at www.muraloncology.com and follow us on LinkedIn and X .
Contact:
Katie Sullivan
